J P Costantino

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings
    J P Costantino
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA
    Ann N Y Acad Sci 949:280-5. 2001
  2. ncbi request reprint Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view
    J P Costantino
    University of Pittsburgh, Graduate School of Public Health, 130 DeSoto Street, Room 316 Parran Hall, Pittsburgh, PA 15261, USA
    Clin Breast Cancer 2:41-6. 2001
  3. ncbi request reprint Reminiscence of Samuel H. Wieand: the NSABP Years
    Joseph P Costantino
    NSABP Biostatistical Center, 201 N Craig Street, Suite 350, Pittsburgh, PA 15213, USA
    Lifetime Data Anal 14:16-7. 2008
  4. ncbi request reprint The impact of hormonal treatments on quality of life of patients with metastatic breast cancer
    Joseph Costantino
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261, USA
    Clin Ther 24:C26-42. 2002
  5. ncbi request reprint Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
  6. ncbi request reprint Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania, USA
    Cancer 110:1929-36. 2007
  7. pmc Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
    David N Krag
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Lancet Oncol 11:927-33. 2010
  8. pmc Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials
    Neal W Wilkinson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Ann Surg Oncol 17:959-66. 2010
  9. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
  10. ncbi request reprint Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
    J Clin Oncol 14:1982-92. 1996

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings
    J P Costantino
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA
    Ann N Y Acad Sci 949:280-5. 2001
    ..This paper summarizes the uses of B/rA in the clinical practice and clinical trial settings and describes the constraints of the methodology as it is being applied to the assessment of therapy with SERMs...
  2. ncbi request reprint Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view
    J P Costantino
    University of Pittsburgh, Graduate School of Public Health, 130 DeSoto Street, Room 316 Parran Hall, Pittsburgh, PA 15261, USA
    Clin Breast Cancer 2:41-6. 2001
    ..The drug cannot be used indiscriminately due to the potential side effects, but benefit/risk assessment methodology can be used to identify substantial numbers of women in whom treatment would provide a net beneficial effect...
  3. ncbi request reprint Reminiscence of Samuel H. Wieand: the NSABP Years
    Joseph P Costantino
    NSABP Biostatistical Center, 201 N Craig Street, Suite 350, Pittsburgh, PA 15213, USA
    Lifetime Data Anal 14:16-7. 2008
  4. ncbi request reprint The impact of hormonal treatments on quality of life of patients with metastatic breast cancer
    Joseph Costantino
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261, USA
    Clin Ther 24:C26-42. 2002
    ..Hormonal therapy (HT) is often used to treat hormone receptor-positive MBC, with the primary treatment goal of reducing both disease burden and patient suffering...
  5. ncbi request reprint Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
    ..To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992...
  6. ncbi request reprint Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania, USA
    Cancer 110:1929-36. 2007
    ..Uncertainties continue to exist concerning the outcomes and management of small (T1a/b N0 M0) invasive breast cancers...
  7. pmc Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
    David N Krag
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Lancet Oncol 11:927-33. 2010
    ....
  8. pmc Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials
    Neal W Wilkinson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Ann Surg Oncol 17:959-66. 2010
    ....
  9. ncbi request reprint Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  10. ncbi request reprint Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
    J Clin Oncol 14:1982-92. 1996
    ....
  11. ncbi request reprint Long-term tamoxifen citrate use and potential ocular toxicity
    M B Gorin
    Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pennsylvania 15213, USA
    Am J Ophthalmol 125:493-501. 1998
    ..To estimate the prevalence of abnormalities in visual function and ocular structures associated with the long-term use of tamoxifen citrate...
  12. ncbi request reprint Is sentinel node biopsy necessary in conservatively treated DCIS?
    Thomas B Julian
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, Pennsylvania, USA
    Ann Surg Oncol 14:2202-8. 2007
    ..Its use in patients with DCIS versus local excision (LE), observation, and/or breast irradiation remains in question...
  13. pmc Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer
    Victor G Vogel
    NSABP, Pittsburgh, PA 15212, USA
    Cancer Prev Res (Phila) 3:696-706. 2010
    ..These results have important public health implications and clarify that both raloxifene and tamoxifen are good preventive choices for postmenopausal women with elevated risk for breast cancer...
  14. ncbi request reprint National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ
    Victor G Vogel
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 3180, USA
    Clin Cancer Res 9:495S-501S. 2003
    ..Outcomes will include both ipsilateral and contralateral new breast cancer and recurrences, as well as the occurrence of regional and distant disease. Enrollment will begin in early 2003...
  15. ncbi request reprint Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR)
    W M Cronin
    NSABP Biostatistical Center, Pittsburgh, PA NSABP, Pittsburgh, PA University of Pittsburgh, Pittsburgh, PA
    J Clin Oncol 26:6518. 2008
    ..We have now analyzed STAR data on adherence (taking 2 pills per day) and persistence (willingness to remain on the protocol regimen)...
  16. ncbi request reprint Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators
    S E Reis
    Cardiovascular Institute, University of Pittsburgh Medical Center, PA 15213, USA
    J Natl Cancer Inst 93:16-21. 2001
    ..The National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (BCPT) is the only clinical trial that provides data to assess the cardiovascular effects of tamoxifen in women with and without CHD...
  17. ncbi request reprint Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  18. ncbi request reprint The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project
    D Lawrence Wickerham
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    World J Surg 30:1138-46. 2006
    ....
  19. pmc Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial
    Sandra M Swain
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Breast Cancer Res Treat 113:315-20. 2009
    ..These results can be used to inform premenopausal women about the risk and time course of amenorrhea associated with this common adjuvant therapy regimen, along with the effects on symptoms and QOL...
  20. ncbi request reprint Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel
    Alphonse G Taghian
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Graduate School of Public Health, University of Pittsburgh, PA, USA
    J Clin Oncol 24:3927-32. 2006
    ..In this study, we assess patterns of locoregional failure (LRF) in LN-negative patients who underwent mastectomy, either with or without adjuvant chemotherapy or hormonal therapy and without postmastectomy radiation therapy (PMRT)...
  21. ncbi request reprint The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
    Victor G Vogel
    The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
    Clin Breast Cancer 3:153-9. 2002
    ..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast..
  22. ncbi request reprint Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system?
    J Wang
    University at Buffalo, State University of New York, Buffalo, NY National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA Aultman Cancer Center, Canton, OH National Surgical Adjuvant Breast and Bowel Project Operations Center, Pittsburgh, PA
    J Clin Oncol 26:11037. 2008
    ..This study reports the confirmatory result using patients included in prospective, randomized clinical trials by the NSABP...
  23. ncbi request reprint Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients
    D N Krag
    National Surgical Adjuvant Breast and Bowel Project and University of Vermont, Burlington, VT National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and the University of Pittsburgh, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Aultman Cancer Center, Canton, OH
    J Clin Oncol 28:LBA505. 2010
    ..It was designed to detect a survival difference of 2% between the 2 groups at 5 years...
  24. ncbi request reprint Is boost therapy necessary in the treatment of DCIS?
    T B Julian
    NSABP Operations and Biostatistical Center, Pittsburgh, PA Allegheny General Hospital, Pittsburgh, PA University of Pittsburgh, Pittsburgh, PA William Beaumont Hospital, Royal Oak, MI Virginia Commonwealth University Medical Center, Massey Cancer Center, Richmond, VA Aultman Cancer Center, Canton, OH
    J Clin Oncol 26:537. 2008
    ..The benefit of boost therapy in patients with DCIS is less certain. We carried out a review of NSABP B-24 to assess the benefit of boost therapy in this randomized trial...
  25. ncbi request reprint Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 295:2742-51. 2006
    ..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown...
  26. ncbi request reprint Breast cancer risk factors and mammographic breast density in women over age 70
    Francesmary Modugno
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Breast Cancer Res Treat 97:157-66. 2006
    ..Breast density is a strong risk factor for breast cancer, but little is known about factors associated with breast density in women over 70...
  27. ncbi request reprint Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:5113-20. 2007
    ..We describe the effectiveness of several interventions and of observational factors...
  28. ncbi request reprint Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2205-11. 2007
    ..Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments...
  29. ncbi request reprint Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
    ..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)...
  30. pmc Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer
    Stewart J Anderson
    Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    J Clin Oncol 27:2466-73. 2009
    ..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease...
  31. pmc Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Departmentof Biostatistics, Graduate School of Public Health, University of Pittsburgh, USA
    J Clin Oncol 28:1677-83. 2010
    ....
  32. pmc Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistics Center, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 28:3929-36. 2010
    ..We report the definitive patient-reported outcomes (PRO) comparisons...
  33. ncbi request reprint Nonparametric inference on median residual life function
    Jong Hyeon Jeong
    Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Biometrics 64:157-63. 2008
    ....
  34. ncbi request reprint Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study
    R Day
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA, USA
    J Natl Cancer Inst 93:1615-23. 2001
    ....
  35. ncbi request reprint Validation studies for models projecting the risk of invasive and total breast cancer incidence
    J P Costantino
    National Surgical Adjuvant Breast and Bowel Project, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, PA, USA
    J Natl Cancer Inst 91:1541-8. 1999
    ..We assessed the validity of both models by employing data from women enrolled in the Breast Cancer Prevention Trial...
  36. ncbi request reprint S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer
    J Bryant
    NSABP, University of Pittsburgh, PA 15213, USA
    Breast Cancer Res Treat 51:239-53. 1998
    ..The diversity of risk in the B-14 population was more extreme than is generally recognized. The prognostic capabilities of S-phase, tumor size, and PgR status were sharply attenuated as the time from surgery increased...
  37. pmc The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project
    D Lawrence Wickerham
    NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Semin Oncol 35:522-9. 2008
    ....
  38. doi request reprint A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    Clin Breast Cancer 8:287-92. 2008
    ..Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator...
  39. ncbi request reprint Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Natl Cancer Inst 97:1652-62. 2005
    ..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings...
  40. ncbi request reprint Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
    Neil Abramson
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Natl Cancer Inst 98:904-10. 2006
    ..However, the involvement of hypercoagulability factors in this association is unclear...
  41. ncbi request reprint The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40
    H D Bear
    Virginia Commonwealth University Massey Cancer Center, Richmond, VA NSABBP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA University of Pittsburgh Medical Center, Magee Womens Cancer Program, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA NSABP CHUM Hotel Dieu, Montreal, QC, Canada SCCC CCOP, Winston Salem, NC San Juan MBCCOP, San Juan, PR University of California, Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA Kaiser Permanente Northern California, Vallejo, CA NSABP Colorado Cancer Research Program, Denver, CO NSABP Northwest Medical Specialties, Tacoma, WA NSABP Kansas City CCOP, Kansas City, MO Jewish General Hospital, McGill University, Montreal, QC, Canada Genesys Regional Medical Center, Flint, MI Dayton CCOP, Dayton, OH Washington Cancer Institute, Washington Hospital Center, Washington, DC National Surgical Adjuvant Breast and Bowel Project and Aultman Health Foundation, Canton
    J Clin Oncol 29:LBA1005. 2011
    ..Secondary aims included assessment of clinical complete response (cCR) rates...
  42. ncbi request reprint Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT)
    S R Land
    University of Pittsburgh Cancer Institute, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA University of California, Los Angeles Schools of Medicine and Public Health, Los Angeles, CA
    J Clin Oncol 29:1505. 2011
    ..We present the risk of cancer at the most common sites, based on the participants' baseline self-reported cigarette smoking, alcohol use, and leisure-time physical activity...
  43. pmc Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer
    Yu Shen
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    J Natl Cancer Inst 100:1448-53. 2008
    ..Its effect on the time to first diagnosis of breast cancer has not been reported. We used information from the randomized, placebo-controlled Breast Cancer Prevention Trial (BCPT) to make that evaluation...
  44. ncbi request reprint Pathologic variables predictive of breast events in patients with ductal carcinoma in situ
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    Am J Clin Pathol 128:86-91. 2007
    ..The similar predictive role of comedo necrosis in this study and that reported previously from NSABP B-17 (total of 2,079 patients) strongly supports its role as a simple high-risk predictor for ipsilateral breast tumor recurrences...
  45. ncbi request reprint Multivariate predictors of failed prehospital endotracheal intubation
    Henry E Wang
    Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Acad Emerg Med 10:717-24. 2003
    ..This study sought to use multivariate logistic regression to identify a set of factors associated with failed adult out-of-hospital ETI...
  46. ncbi request reprint Is tamoxifen a risk factor for retinal vaso-occlusive disease?
    Michael B Gorin
    Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Retina 25:523-6. 2005
  47. pmc The use of tamoxifen and raloxifene for the prevention of breast cancer
    D Lawrence Wickerham
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Allegheny Center, Pittsburgh, PA 15212, USA
    Recent Results Cancer Res 181:113-9. 2009
    ..51 vs 2.11 per 1,000; RR, 1.40; 95% CI, 0.98-2.00). There were 36 cases of uterine cancer with tamoxifen and 23 cases with raloxifene (RR, 0.63; 95% CI, 0.35-1.08)...
  48. ncbi request reprint Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial
    T B Julian
    National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA William Beaumont Hospital, Royal Oak, MI Radiation Therapy Oncology Group and Medical College of Wisconsin, Milwaukee, WI RTOG Statistical Center, Philadelphia, PA National Surgical Adjuvant Breast and Bowel Project and Virginia Commonwealth University, Richmond, VA National Surgical Adjuvant Breast and Bowel Project and Arizona Breast Cancer Specialists, Scottsdale, AZ NSABP University of Colorado, Aurora, CO NSABP and Allegheny General Hospital, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Aultman Health Foundation, Canton, OH Radiation Therapy Oncology Group and Emory University, Atlanta, GA
    J Clin Oncol 29:1011. 2011
    ..Given those results, we believe it necessary to report the current levels of toxicity in the 3-D conformal portion of the APBI arm of our trial...
  49. ncbi request reprint Correlation of serum sex hormone levels with the Gail model risk of breast cancer in postmenopausal women
    H Liang
    University of Pittsburgh Cancer Institute, Pittsburgh, PA Loyola University Medical Center, Maywood, IL University of Pittsburgh, Pittsburgh, PA University of Pitsburgh, Pittsburgh, PA
    J Clin Oncol 26:1517. 2008
    ..The objective of this study was to determine whether serum estradiol and free testosterone levels in post-menopausal women correlated with their predicted risk of breast cancer...
  50. ncbi request reprint Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial
    K Shen
    Precision Therapeutics, Inc, Pittsburgh, PA NSABBP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA
    J Clin Oncol 29:1029. 2011
    ..Performance was assessed by the prediction of pathological complete response (pCR) in National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27 clinical trial breast cancer patients...
  51. ncbi request reprint 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1
    E Amir
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA University of California, Los Angeles Schools of Medicine and Public Health, Los Angeles, CA Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project and Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA Mount Sinai Hospital, Toronto, ON, Canada
    J Clin Oncol 29:1528. 2011
    ..Obesity and low VitD are associated with insulin resistance, inflammation and elevated adipocytokines such as leptin. We have examined associations of obesity, VitD and these related factors with BC risk...
  52. ncbi request reprint Vibroacoustic stimulation enhances visualization of the four-chamber cardiac view in the third trimester
    N Lazebnik
    Department of Obstetrics, Magee Womens Research Institute, Pittsburgh, USA
    Ultrasound Obstet Gynecol 8:309-13. 1996
    ..1 and 37.0 weeks. We conclude that in a selected group of patients vibroacoustic stimulation can be used to enhance visualization of the four-chamber view...
  53. ncbi request reprint Issues and findings in the evaluation of occupational risk among women high nickel alloys workers
    V C Arena
    Department of Biostatistics, University of Pittsburgh, PA 15261, USA
    Am J Ind Med 36:114-21. 1999
    ..All the plants were located within the United States and cohort eligibility required some work experience within the period of the late 1940s through the mid 1960s...
  54. ncbi request reprint Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data
    Jong Hyeon Jeong
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Invest 24:288-93. 2006
    ..The progesterone level does not affect the size of benefit from tamoxifen, but the benefit from the addition of the chemotherapy is greater for patients with higher progesterone level...
  55. ncbi request reprint Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women
    David Cella
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Breast Cancer Res Treat 109:515-26. 2008
    ..To evaluate scalability of a symptom scale administered to women enrolled in the Breast Cancer Prevention Trial (BCPT) (P-1) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP)...
  56. ncbi request reprint Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk
    Patricia K Agatisa
    Department of Obstetics and Gynecology, School of Medicine, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Am J Physiol Heart Circ Physiol 286:H1389-93. 2004
    ..006). These data demonstrate that women with a history of preeclampsia exhibit impaired endothelial function up to 1 yr postpartum. This observation may explain their increased risk for hypertension and cardiovascular disease...
  57. ncbi request reprint Projecting individualized absolute invasive breast cancer risk in African American women
    Mitchell H Gail
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Executive Plaza South Rm 8032, Bethesda, MD 20892 7244, USA
    J Natl Cancer Inst 99:1782-92. 2007
    ..We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool...
  58. ncbi request reprint Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial
    Mary Cushman
    Department of Medicine, University of Vermont, Burlington, VT, USA
    Br J Haematol 120:109-16. 2003
    ..Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment...
  59. ncbi request reprint Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)
    Mary S Beattie
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    J Natl Cancer Inst 98:110-5. 2006
    ..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population...
  60. doi request reprint Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....
  61. ncbi request reprint Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
    ..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women...
  62. ncbi request reprint Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial
    Eva Chalas
    Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University, State University of New York, Stony Brook, NY
    Am J Obstet Gynecol 192:1230-7; discussion 1237-9. 2005
    ..This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project...
  63. ncbi request reprint Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  64. ncbi request reprint Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    Victor G Vogel
    J Natl Cancer Inst 94:1504. 2002
  65. ncbi request reprint Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
    David N Krag
    University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
    Lancet Oncol 8:881-8. 2007
    ..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone...